Close to 30% of retina specialists in the United States are now affiliated with private-equity-backed practices, according to a Health Affairs study published in 2025. That concentration took only a few years to assemble. And the same private equity model that built it's now beginning to take it apart, selling entire subspecialty lines to new corporate owners. For any physician who has hesitated at ownership because the whole landscape looks unstable and prone to getting flipped, the direction of these sales is the single most clarifying fact available, because it shows you exactly where the instability lives and, just as importantly, where it does not.

The Fear Worth Naming Precisely

The fear sounds like this. I could step into ownership, pour years of my life into building something real, and then watch it get sold out from under me, the way I have watched practices get flipped again and again across this specialty. Why take on all of that risk and effort just to end up inside the same churn I was trying to escape?

It's a reasonable fear and it's built on accurate observation. Practices do get flipped. Ownership has, for a great many physicians, come to feel like a precarious thing that some larger entity can sell on a whim, with the doctors attached to it along for the ride. But the fear contains a hidden assumption that deserves to be pulled out into the light and examined, because everything turns on it. The assumption is that the flipping comes from ownership itself, when it actually comes from one specific ownership model, the private equity rollup. Conflating the two is exactly what turns a sensible, evidence-based wariness into a blanket reason to avoid ownership of any kind.

Why Private Equity Must Sell, Always

To see the distinction clearly you've to understand the engine underneath a private equity platform, because the engine is what guarantees the sale. A private equity fund raises money from investors on an explicit promise: the fund has a finite life, usually around 10 years, and within that life it will buy businesses, improve or grow them, sell them, and return the capital to investors with a profit on top. Every acquisition a fund makes is therefore made with the sale already planned. The fund doesn't buy a practice to own it. It buys a practice to sell it, on a timeline the fund's own structure dictates, because returning capital to investors is the whole reason the fund exists.

That's why the instability reads as the design functioning exactly as intended rather than as a betrayal or a failure. A fund that bought practices and then held them forever would be a fund that failed its investors and could never raise another dollar. The selling is mandatory, baked into the legal and economic structure of what a private equity fund is. So when a physician inside a private equity platform watches their practice get sold, re-sold, and re-rolled, they're watching the machine do the one thing it was built to do, working perfectly rather than breaking down.

What the Sell-Offs Actually Prove

Watch what private equity is currently doing with its ophthalmology holdings and the point becomes impossible to miss. Several of the largest platforms have concluded that they can't run every subspecialty well, and they're divesting whole lines. The clearest evidence sits at the very top of the market. In early 2025, Cencora, a pharmaceutical distribution giant, acquired Retina Consultants of America in a deal valued in the billions, taking a majority stake. In the same general period, McKesson, another distribution giant, acquired a controlling interest in PRISM Vision, a transaction heavily weighted toward retina. These are enormous, subspecialty-specific deals, and they tell you that the private equity owners of these assets are sellers, restructuring their holdings and handing entire physician populations to new corporate parents.

That's the churn the original fear is actually about, and it's happening inside the private equity model, to physicians who are employees or rollover-equity holders within it. The retina specialists in those platforms didn't choose to be sold to a pharmaceutical distributor. It happened to them, because the model they were part of is built to buy, restructure, and sell on schedule. The Health Affairs research adds a clinical dimension that makes the stakes even sharper, finding that private-equity-acquired practices reduced the number of retinal detachment repairs by nearly 20% after acquisition, a measure of how deeply the ownership model can reshape even the practice of medicine itself, not merely the org chart above it.

Where Stability Actually Comes From

Now set that against what physician ownership of a permanently held practice looks like, and notice that the difference is structural rather than a matter of good intentions. The instability in the private equity model comes from a specific, named source: the fund has a finite life, it must return capital to its investors, and so it must eventually sell whatever it bought. Remove that engine and the compulsion to sell disappears with it.

A model built to hold practices permanently has no fund life forcing a sale, no investor clock demanding an exit by a certain date, no mandate to buy a subspecialty line and then divest it 3 years later when the strategy shifts. The practice is meant to be held, operated, and eventually passed on, rather than packaged and resold to the next financial buyer. The stability comes from a structural fact rather than a brochure promise: there's no finite-life fund with a return obligation forcing the sale in the first place. Take away the engine and you take away the churn it produces.

The Inversion You Should See

So the fear inverts completely once you trace it to its source. The physician who avoids ownership because they're afraid of getting flipped is, in a great many cases, choosing employment inside the exact structure that does the flipping. Remaining an employee of a private equity platform offers no refuge from the churn. It's a seat inside the machine that generates it, with no control over when the sale comes, what price it comes at, or who the next owner turns out to be. Owning a permanently held practice is the actual escape from the dynamic the fear is genuinely about, rather than a fresh exposure to it.

The retina sell-offs work as a demonstration rather than a warning against ownership. At the largest scale the specialty has, they show which ownership model carries the instability and which one is built to avoid it. Verdira holds practices permanently. There's no fund life, no exit mandate, and no plan to assemble a subspecialty line and sell it to a distributor when the math changes. The doctor who feared being flipped was right to fear it. They were simply looking at the wrong structure when they concluded that ownership itself was the thing to stay away from.

This article is for general educational purposes and isn't financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a physician exploring ownership, we're open to thoughtful conversations. Contact info@verdira.com | 307-381-3734 | verdira.com Images are AI-generated illustrations and do not depict actual Verdira practices, physicians, or patients.